Close Menu


While RXi continues to bill itself as an RNAi drug developer, a company official indicated this week that the firm may expand its focus into the miRNA field as it works to meet its goal of defining its areas of therapeutic interest by the end of the second quarter.

IP Update: Apr 15, 2010


USPTO Publishes Six Patents, Eight Patent Applications Related to RNAi

The company said that the move will allow patients to use its miRNA test without having to undergo more invasive procedures to obtain tumor samples.

Papers of Note: Apr 8, 2010


RNAi- and microRNA-Related Papers Published March 2010

IP Update: Apr 1, 2010


USPTO Publishes Two Patents, Eight Patent Applications Related to RNAi

People in the News: Apr 1, 2010


Lyle Arnold

Rosetta reported revenues of $119,000 for the fourth quarter compared to no revenues in Q3 2009 and the comparable period of Q4 2008. The firm's first three tests were launched late in the year.

The College of American Pathologists has accredited Rosetta's lab, which offers microRNA-based tests.

Matthais Selbach

Rosetta's president and CEO also noted that the company continues to work in the miRNA therapeutics space, but indicated that its collaboration with Regulus Therapeutics to develop a liver cancer drug has officially ended.


President Donald Trump announced the US would be leaving the World Health Organization, NBC News reports.

A study of Great Danes homes in on a genomic region linked to fearfulness.

CDC head says a new analysis indicates earlier testing wouldn't have caught viral spread, NPR reports.

In PLOS this week: gene expression and epigenetics of Indonesian populations, hookworm parasite secretome, and more.